Effects of a Hip Flexor and Extensor Muscle Training Program in Individuals with Chronic Mechanical Low Back Pain

January 16, 2025 updated by: Lucía Pilar Vicente Pina

The goal of this clinical trial is to evaluate the effect of a physiotherapy intervention program in the lumbopelvic area in chronic low back pain patients. The main questions it aims to answer are:

  1. Is a specific stretching and strengthening program for the hip musculature beneficial for function and symptom reduction in patients with non-specific chronic low back ain?
  2. Are patients who have greater hip extension dysfunction going to benefit more from a specific program of stretching and strengthening of hip muscles?
  3. Are there more alteration in pelvis alignement and movement in standig position compared to seated position in those patiens with lesser hip range of movement?
  4. Are patiens with lesser hip range of movement going to show more dysfunction in the lumbopelvic region?

Participants will:

  • Visit the physiotherapy clinic once a week to complete the therapeutic exercise session.
  • Repeat the session in their houses if its possible between 3 or 4 times a week and record the number of days they repeat the session at home.
  • Answer some questionaires at the begining of the intervention, after 4 weeks, a month and three months.

Study Overview

Detailed Description

This study aims to enhance healthcare interventions for chronic low back pain, focusing specifically on patients whose pain may be linked to restricted hip extension mobility. Patients will be referred from the healthcare system to the physiotherapy center, where the principal investigator, Lucía Vicente, will randomize participants into either the intervention or control group. Each participant will complete an initial evaluation at the start of the intervention and again after 4 weeks. Additional questionnaires will be administered one and three months post-intervention. Pelvic movement changes will also be tracked before each in-person session. The program will focus on strengthening the pelvic muscles, particularly by targeting hip extensor strengthening and hip flexor stretching.

Study Type

Interventional

Enrollment (Estimated)

50

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

      • Zaragoza, Spain, 50009
        • Centro Clinico de Fisioterapia OMT
        • Contact:
        • Contact:
          • César Hidalgo García

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Age greater than 18 and less than 70 years.
  • Low back pain lasting more than 3 months defined as: "Pain or discomfort localized below the costal margin and above the gluteal fold, with or without referred pain to the leg."
  • Low back pain with a mechanical component.
  • Signed informed consent prior to participation in the study.

Exclusion Criteria:

  • A specific cause for their low back pain (trauma, spondylolisthesis, vertebral fractures, etc.), have undergone any surgical procedures on the spine or hip, or have other diseases or conditions (neurological issues, joint replacements, etc.).
  • Cognitive impairment and inability to comprehend.
  • Injections in the last 6 months or physiotherapy treatment in the last 3 months.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Public healthcare treatment
Participants will receive four weeks of convetional active treatment for chronic low back pain at the healthcare center.

The patients will receive 10 physiotherapy sessions at the health center throughout 4 weeks.They will be taught active exercises and undergo passive therapies to address their low back pain. Each session will last approximately 30 minutes.

The intervention will therefore be variable depending on the assigned physiotherapist, as there is no standardized protocol for action.

Experimental: Program to improve lumbopelvic function
The program will consist of a mixed model of in-person and home-based sessions. In-person sessions will be once a week and supervised by a physiotherapist. After each session participants will be encourage to replicate that session at home as many times as possible. Each session will include a warm-up, a strengthening phase, and a stretching phase. The strengthening part will be performed using a low-load methodology, which is the best alternative for home-based training. Specifically, the training will focus on stretching the hip flexors and strengthening the hip extensors.

Each individual will receive a weekly session log at the start of the intervention, allowing them to record the total number of sessions performed between in-person visits and the perceived exertion.

In the strengthening phase, both compound and isolated exercises will be performed. These exercises will be of low intensity and maintained for prolonged periods until the patient reaches fatigue or can no longer perform the repetitions correctly. If the patient reaches 40 repetitions, the exercise will be progressed in difficulty. The patient will have one minute of rest after each set.

Each session will include a total of 4 sets focused on the gluteal muscles The speed of execution for each repetition will be between 4-6 seconds. After the strengthening phase, three unilateral static stretches targeting the hip flexors will be performed, each lasting one minute.

The entire program will be performed using bodyweight exercises and adapted exercises that can be done at home.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Hip flexors range of movement
Time Frame: From the enrollement to the end of the treatment at 4 weeks
Range of motion of the hip flexors will be assessed using the Modified Thomas Test, also recording the body area where the sensation of stretch is felt, as well as the intensity.
From the enrollement to the end of the treatment at 4 weeks
Hip flexors range of movement
Time Frame: From the enrollement to the end of the treatment at 4 weeks
Range of motion of the hip flexors will be assessed using The modified Ober test, also recording the body area where the sensation of tension or stretch is felt, as well as the intensity.
From the enrollement to the end of the treatment at 4 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Pain
Time Frame: From enrollment through the end of the 4-week treatment, and again one month after.
Low back pain will be assessed using a visual analog scale (VAS). Information on average pain over the last 3 days, the maximum pain experienced, and the current pain level will be collected. The patient will mark their pain level with a line on scale ranging from 0 to 100 millimeters, where "0" represents no pain and "100" represents the worst imaginable pain, in relation to daytime pain (average VAS perceived over the last 3 days and at the present moment). Additionally, patients will be asked about the location and intensity of other symptoms using a Likert scale and a body map.
From enrollment through the end of the 4-week treatment, and again one month after.
Oswestry Disability Index
Time Frame: From enrollment through the end of the 4-week treatment, and again one month after.
It is a questionnaire composed of 10 categories: (1) pain intensity, (2) self-care, (3) lifting objects, (4) walking, (5) sitting, (6) standing, (7) sleeping, (8) sexual life, (9) social life, and (10) traveling. Each category consists of 6 items scored from 0 to 5, with a score of 0 on the first statement and 5 on the last. A mark at the highest levels indicates that the person is in worse condition. The questionnaire includes an additional question about previous treatments. If more than one response is selected, the highest score is considered. If all 10 sections are completed, the score is calculated as follows: the maximum score for the 10 sections is 50 points. If all sections are completed, this number is converted into a percentage with a total of 100. The Spanish version of the questionnaire shows good reliability and validity with an ICC between 0.89-0.97 and was validated in Spanish.
From enrollment through the end of the 4-week treatment, and again one month after.
Pelvis saggital movement
Time Frame: From the enrollement to the end of the treatment at 4 weeks. For participants enrolled in the program to improve lumbopelvic function, this assessment will also be performed after each physiotherapy session.
The pelvic movement will be recorded in video format in the sagittal plane for each patient in both standing and sitting positions with 45° of hip flexion. In each measurement it will be registered the range of movemento of the pelvis. The movement consist of the total range of anterior and posterior rotation of the pelvis.
From the enrollement to the end of the treatment at 4 weeks. For participants enrolled in the program to improve lumbopelvic function, this assessment will also be performed after each physiotherapy session.
Pain during pelvic tilting
Time Frame: From the enrollement to the end of the treatment at 4 weeks. For participants enrolled in the program to improve lumbopelvic function, this assessment will also be performed after each physiotherapy session.
Pain during pelvic tilting will be assessed using a visual analog scale (VAS). The patient will mark their pain level with a line on scale ranging from 0 to 100 millimeters, where "0" represents no pain and "100" represents the worst imaginable pain. Additionally, patients will be asked about the location using a a body map and also the movement phase where the pain appears or is at its worst.
From the enrollement to the end of the treatment at 4 weeks. For participants enrolled in the program to improve lumbopelvic function, this assessment will also be performed after each physiotherapy session.

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Force in Newtons by a Maximum voluntary isometric contraction (MVIC) test
Time Frame: From the enrollement to the end of the treatment at 4 weeks
A maximum voluntary isometric contraction (MVIC) test will be performed for the biceps femoris, gluteus maximus and tensor fasciae latae using a load cell.
From the enrollement to the end of the treatment at 4 weeks
Dynamic Activation Assessment during walking
Time Frame: From the enrollement to the end of the treatment at 4 weeks

To assess dynamic activation, a gait test will be used. The gait test will involve walking on a treadmill for one minute at a comfortable speed, chosen by each patient. Two repetitions will be performed. Additionally, each subject will have an adaptation period to ensure they feel comfortable during the test.

To assess activation, internal oblique, lumbar multifidus, gluteus maximus, and tensor fasciae lataewill be recorded simultaneously.

The total percentage of activation for each muscle during the central 30 seconds of the test will be calculated.

In addition, the speed achieved by each participant will also be recorded.

From the enrollement to the end of the treatment at 4 weeks
Anthropometric Data (weight)
Time Frame: From the enrollement to the end of the treatment at 4 weeks
Weight in kq using the Tanita TBF-300, Amsterdam, Belgium
From the enrollement to the end of the treatment at 4 weeks
Sleep Quality
Time Frame: From the enrollement to the end of the treatment at 4 weeks, and a month after.
The MOS Sleep Scale (Sleep Scale from the Medical Outcomes Study) will be used, which has proven to be a valid and reliable tool.
From the enrollement to the end of the treatment at 4 weeks, and a month after.
Kinesiophobia
Time Frame: From enrollment through the end of the 4-week treatment, and again one month after.
The Tampa Scale for Kinesiophobia-11 (TSK-11) is a self-administered questionnaire recommended by the clinical guidelines for neuropathic pain assessment to measure fear of movement. It consists of 11 items assessing two factors: Activity Avoidance and Fear of Harm. Each item is rated on a 4-point Likert scale ranging from strongly disagree to strongly agree. High scores indicate a greater degree of kinesiophobia.
From enrollment through the end of the 4-week treatment, and again one month after.
Sensitization Questionnaire
Time Frame: From enrollment through the end of the 4-week treatment, and again one month after.
This instrument measures symptoms related to central sensitization syndromes. Part A assesses 25 common symptoms related to central sensitization syndromes, with a total score ranging from 0 to 100. Part B (not scored) asks if the participant has been diagnosed with one or more specific conditions, including seven different central sensitization syndromes.
From enrollment through the end of the 4-week treatment, and again one month after.
Pain Catastrophizing Scale (PCS)
Time Frame: From the enrollement to the end of the treatment at 4 weeks, and a month after.
The PCS is a 13-item self-administered scale and one of the most widely used to assess pain catastrophizing. It comprises three dimensions: a) rumination, b) magnification, and c) helplessness. The theoretical range of the scale is between 13 and 62, with lower scores indicating low catastrophizing and higher scores indicating severe catastrophizing.
From the enrollement to the end of the treatment at 4 weeks, and a month after.
COOP-WONCA Charts
Time Frame: From the enrollement to the end of the treatment at 4 weeks
These charts assess health-related quality of life or perceived health. The questionnaire consists of 6 charts on health status and a total of 7 questions with five possible answers.
From the enrollement to the end of the treatment at 4 weeks
Mental Health Status
Time Frame: From enrollment through the end of the 4-week treatment, and again one month after.
Assessed using the validated Spanish version of the GHQ-12 (General Health Questionnaire), which evaluates overall psychological well-being to detect non-psychotic psychiatric problems.The total score ranges from 0 to 12, with higher scores indicating poorer mental health. A cutoff score above 3 suggests psychological distress.
From enrollment through the end of the 4-week treatment, and again one month after.
Emotional and Social Support
Time Frame: From enrollment through the end of the 4-week treatment, and again one month after.
Assessed using the DUKE-UNC-11 (Duke-UNC Functional Social Support Questionnaire).The total score ranges from 11 to 55, categorizing the individual's perceived social support as "low" (below 32) or "normal" (32 or above)
From enrollment through the end of the 4-week treatment, and again one month after.
Dynamic Activation Assessment durign Pelvic tilt
Time Frame: From the enrollement to the end of the treatment at 4 weeks

To assess dynamic activation, a pelvic mobility test will be used. To assess activation, internal oblique, lumbar multifidus, gluteus maximus, and tensor fasciae lataewill be recorded simultaneously.

The pelvic mobility test will be the same one used to analyze biomechanical variables. It will consist of an assessment in both standing and seated positions at 45° flexion, during which the electromyographic activity of the aforementioned muscles will be recorded simultaneously. The percentage of muscle activation during anterior and posterior pelvic tilts will be calculated in both standing and seated positions.

From the enrollement to the end of the treatment at 4 weeks
Walking speed
Time Frame: From the enrollement to the end of the treatment at 4 weeks

The gait test will involve walking on a treadmill for one minute at a comfortable speed chosen by each patient. Two repetitions will be performed. Additionally, each subject will have an adaptation period to ensure they feel comfortable during the test.

The speed achieved by each participant will be recorded, as lower speeds are associated with protective mechanisms.

From the enrollement to the end of the treatment at 4 weeks
Muscle activity during a Maximum voluntary isometric contraction (MVIC) test
Time Frame: From the enrollement to the end of the treatment at 4 weeks

A maximum voluntary isometric contraction (MVIC) test will be performed for the biceps femoris, gluteus maximus, lumbar multifidus, internal oblique , and tensor fasciae latae using a wireless surface electromyography (EMG) system (Trigno Avanti, Delsys, Natick, USA).

The electrode placement will follow the SENIAM recommendations. Each test will be performed for 3 seconds with 20 secons rest. The percentage of activation and peak activation will be recorded for each test.

From the enrollement to the end of the treatment at 4 weeks
Anthropometric Data (Height)
Time Frame: At the begining of the enrollement
Height in centimeters using a stadiometer.
At the begining of the enrollement
Body composition, percentage of Fat mass
Time Frame: From the enrollement to the end of the treatment at 4 weeks
Fat mass wil be assessed using the Tanita bioelectrical impedance analyzer, with results expressed as a percentage relative to total body mass.
From the enrollement to the end of the treatment at 4 weeks
waist circumference
Time Frame: From the enrollement to the end of the treatment at 4 weeks
waist circumference using a non-extensible plastic tape (TECSYMP Instruments: 0-2 m).
From the enrollement to the end of the treatment at 4 weeks
Body composition, percentage of muscle mass
Time Frame: From the enrollement to the end of the treatment at 4 weeks
Muscle mass wil be assessed using the Tanita bioelectrical impedance analyzer, with results expressed as a percentage relative to total body mass.
From the enrollement to the end of the treatment at 4 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

March 1, 2025

Primary Completion (Estimated)

December 1, 2025

Study Completion (Estimated)

March 1, 2026

Study Registration Dates

First Submitted

October 21, 2024

First Submitted That Met QC Criteria

January 16, 2025

First Posted (Actual)

March 25, 2025

Study Record Updates

Last Update Posted (Actual)

March 25, 2025

Last Update Submitted That Met QC Criteria

January 16, 2025

Last Verified

January 1, 2025

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • PI24/303

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Chronic Low-back Pain (cLBP)

Clinical Trials on generic health care

Subscribe